Adjuvant radiotherapy after radical prostatectomy: Evidence and analysis

Cancer Treatment Reviews

Volumn 37, Issue 2, 2011, Pages 89-96

  Raldow, Ann ^a   Hamstra, Daniel A ^b   Kim, Sung N ^c,d,e   Yu, James B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Adjuvant radiation therapy; Post operative radiation therapy; Prostate cancer; Radiation therapy

Indexed keywords

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; CYSTITIS; DEATH; DIARRHEA; HUMAN; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PROCTITIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM DISEASE; REVIEW; URETHRA STRICTURE; URINARY FREQUENCY;

COST-BENEFIT ANALYSIS; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY;

EID: 79151470593     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2010.07.001     Document Type: Review

References (65)

1. Jemal A., et al. Cancer statistics 2009. CA Cancer J Clin 2009, 59(4):225-249.
2. Underwood W., et al. Racial treatment trends in localized/regional prostate carcinoma: 1992-1999. Cancer 2005, 103(3):538-545.
3. Bill-Axelson A., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352(19):1977-1984.
4. Cooperberg M.R., et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 2004, 171(4):1393-1401.
5. Klein E.A., et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008, 179(6):2212-2216. discussion 2216-7.
6. Ward J.F., et al. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 2004, 172(4 Pt 1):1328-1332.
7. Bott S.R., et al. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int 2005, 95(1):34-39.
8. Walz J., et al. Risk-adjusted hazard rates of biochemical recurrence for prostate cancer patients after radical prostatectomy. Eur Urol 2009, 55(2):412-419.
9. Touijer K., et al. Oncologic outcome after laparoscopic radical prostatectomy: 10 years of experience. Eur Urol 2009, 55(5):1014-1019.
10. Roehl K.A., et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004, 172(3):910-914.
11. Swanson G.P., Riggs M., Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 2007, 25(2):110-114.
12. Vis A.N., Schroder F.H., van der Kwast T.H. The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol 2006, 50(2):258-265.
13. Dahl D.M., et al. Pathologic outcome of laparoscopic and open radical prostatectomy. Urology 2006, 68(6):1253-1256.
14. Katz M.S., et al. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003, 21(3):483-489.
15. Freedland S.J., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294(4):433-439.
16. Pound C.R., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999, 281(17):1591-1597.
17. Freedland S.J., et al. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006, 176(4 Pt 1):1404-1408.
18. Bolla M., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366(9485):572-578.
19. Thompson I.M., et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009, 181(3):956-962.
20. Wiegel T., et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27(18):2924-2930.
21. King C.R., Kapp D.S. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 2008, 71(2):346-350.
22. Stephenson A.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004, 291(11):1325-1332.
23. Stephenson A.J., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007, 25(15):2035-2041.
24. Trock B.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299(23):2760-2769.
25. Van der Kwast T.H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25(27):4178-4186.
26. Parker C., et al. Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int 2007, 99(6):1376-1379.
27. Eisenberg ML et al. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol 2009 Apr 3 [Epub ahead of print].
28. Supiot S., et al. A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. Radiother Oncol 2008, 88(1):53-60.
29. Swanson G.P., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007, 25(16):2225-2229.
30. Jereczek-Fossa B.A., Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol 2007, 84(2):197-215.
31. Fonteyne V., et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007, 84(2):156-163.
32. De Meerleer G.O., et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol 2007, 82(2):160-166.
33. Krengli M., et al. Intraoperative radiotherapy during radical prostatectomy for locally advanced prostate cancer: technical and dosimetric aspects. Int J Radiat Oncol Biol Phys 2010, 76(4):1073-1077.
34. Rocco B., et al. Intraoperative radiotherapy during radical prostatectomy for intermediate-risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matched-pair analysis. BJU Int 2009, 104(11):1624-1630.
35. Orecchia R., et al. Intraoperative radiotherapy for locally advanced prostate cancer: treatment technique and ultrasound-based analysis of dose distribution. Anticancer Res 2007, 27(5B):3471-3476.
36. Saracino B., et al. Phase I-II study of intraoperative radiation therapy (IORT) after radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71(4):1049-1056.
37. Van Cangh P.J. The increase in minimally invasive endourology - a tribute to excellence and a plea for thoughtful restraint. J Urol 1996, 156(4):1411.
38. Moinpour C.M., et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol 2008, 26(1):112-120.
39. Poortmans P., et al. Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiother Oncol 2007, 84(2):121-127.
40. Michalski J.M., et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 76:361-368.
41. Wiltshire K.L., et al. Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy. Int J Radiat Oncol Biol Phys 2007, 69(4):1090-1099.
42. Sidhom M.A., et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol 2008, 88(1):10-19.
43. Miralbell R., et al. Endorectal MRI assessment of local relapse after surgery for prostate cancer: a model to define treatment field guidelines for adjuvant radiotherapy in patients at high risk for local failure. Int J Radiat Oncol Biol Phys 2007, 67(2):356-361.
44. Silverman J.M. Krebs, TL. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy. AJR Am J Roentgenol 1997, 168(2):379-385.
45. Sella T., et al. Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 2004, 231(2):379-385.
46. Wang K., et al. The uncertainties in target localization for prostate and prostate-bed radiotherapy with Calypso 4D. Int J Radiat Oncol Biol Phys 2009, 75(3):S594.
47. Schiffner D.C., et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 2007, 67(2):610-619.
48. Nath SK Nov 23 [Epub ahead of print]. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009 Nov 23 [Epub ahead of print].
49. Pollack A., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53(5):1097-1105.
50. Zietman A.L., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239.
51. Kupelian P., et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005, 61(2):415-419.
52. Ost P., et al. Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy for prostate cancer: clinical results in 104 patients. Eur Urol 2009, 56(4):669-675.
53. Al-Mamgani A., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-988.
54. Kuban D.A., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
55. Dearnaley D.P., et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92(3):488-498.
56. Cancer facts and figures, 2009.
57. Schulman K.L., Kohles J. Economic burden of metastatic bone disease in the US. Cancer 2007, 109(11):2334-2342.
58. Zubek V.B., Konski A. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment. Mol Diagn Ther 2009, 13(1):31-47.
59. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16(3):199-208.
60. Laupacis A., Sackett D.L., Roberts R.S. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988, 318(26):1728-1733.
61. Cook R.J., Sackett D.L. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995, 310(6977):452-454.
62. Cordell W.H. Number needed to treat (NNT). Ann Emerg Med 1999, 33(4):433-436.
63. L'Abbe K.A., Detsky A.S., O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987, 107(2):224-233.
64. Bill-Axelson A., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100(16):1144-1154.
65. Thompson I.M., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296(19):2329-2335.